Ignite Creation Date:
2024-05-06 @ 7:15 AM
Last Modification Date:
2024-10-26 @ 11:46 AM
Study NCT ID:
NCT02507128
Status:
UNKNOWN
Last Update Posted:
2015-07-23
First Post:
2015-07-22
Brief Title:
Effects of Glucagon Like Peptide-1 on No-reflow
Sponsor:
Chen Wei Ren MD
Organization:
Chinese PLA General Hospital
Study Overview
Official Title:
Effects of Glucagon Like Peptide-1 on No-reflow in Patients With ST-segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
Status:
UNKNOWN
Status Verified Date:
2015-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The investigators planned to evaluate the effects of liraglutide on no-reflow in patients with acute ST-segment elevation myocardial infarction STEMI
Detailed Description:
Acute myocardial infarction AMI is a major cause of mortality and morbidity Primary percutaneous coronary intervention PCI is currently the most effective treatment strategy for AMI Brisk thrombolysis in myocardial infarction TIMI grade 3 flow immediately after PCI in patients with AMI is associated with improved clinical outcomes compared with lower flow grades However myocardial reperfusion is suboptimal in many patients mostly because of the no-reflow phenomenon No-reflow is defined as suboptimal myocardial reperfusion in part of the coronary circulation without angiographic evidence of mechanical vessel obstruction To date however very few drugs have been shown to reverse established no-reflow
Glucagon-like peptide-1 GLP-1 is an incretin hormone that regulates plasma glucose and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction GLP-1 has antioxidant and anti-inflammatory properties and may protect endothelial function Experimental studies have also revealed that GLP-1 or its analogues protect against reperfusion injury in pigs Exenatide a GLP-1 analogue was reported to reduce reperfusion injury in patients with ST-segment elevation myocardial infarction Similarly liraglutide was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice To date however there is no clinical evidence for the effects of liraglutide on no-reflow in patients with AMI Therefore the aim of this study was to evaluate the effects of liraglutide pretreatment on myocardial no-reflow of prime PCI in patients with AMI
Glucagon-like peptide-1 GLP-1 is an incretin hormone that regulates plasma glucose and GLP-1 analogues were recently introduced for the treatment of acute myocardial infarction GLP-1 has antioxidant and anti-inflammatory properties and may protect endothelial function Experimental studies have also revealed that GLP-1 or its analogues protect against reperfusion injury in pigs Exenatide a GLP-1 analogue was reported to reduce reperfusion injury in patients with ST-segment elevation myocardial infarction Similarly liraglutide was reported to reduce cardiac rupture and infarct size and improve cardiac output in normal and diabetic mice To date however there is no clinical evidence for the effects of liraglutide on no-reflow in patients with AMI Therefore the aim of this study was to evaluate the effects of liraglutide pretreatment on myocardial no-reflow of prime PCI in patients with AMI
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None